Natera, Inc. (NTRA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights several positive factors: raised revenue and gross margin guidance, strong cash flow expectations, and strategic investments in new product launches and clinical trials. Despite some vague responses in the Q&A, the overall sentiment is positive due to optimistic guidance, Medicare reimbursement expansion, and AI-driven efficiencies. The raised guidance and strong financial metrics, coupled with the positive outlook for future growth, suggest a likely positive stock price movement over the next two weeks.
Key Financial Performance
Revenue $592 million in Q3 2025, up 35% year-over-year. The increase was driven by strong volume performance and improvements in ASPs across major products.
Clinical MRD Tests Processed 202,000 tests in Q3 2025, representing a growth of more than 21,500 units compared to Q2 2025. This is a 56% year-over-year growth, driven by groundbreaking clinical data and excellent customer experience.
Gross Margin 64.9% in Q3 2025, up almost 3 percentage points year-over-year and 1.5 percentage points quarter-over-quarter. The improvement was due to better ASPs and leaner COGS.
Signatera ASP Approximately $1,200 in Q3 2025, with sequential improvement compared to Q2 2025. Growth was driven by success in working with health plans for reimbursement and better cash collections.
Days Sales Outstanding (DSO) 49 days in Q3 2025, down from 57 days in Q2 2025. This improvement reflects accelerated cash collections.
Free Cash Flow Expected to generate roughly $100 million in cash for the full year 2025, reflecting strong financial performance and operational efficiency.
SG&A Expenses Flat to down between Q2 and Q3 2025, reflecting stabilization in commercial team and revenue cycle operations.
R&D Expenses Increased in Q3 2025 to support multiple new product launches and clinical trial expansions, including 7 new MolDx submissions.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Fetal Focus: Launched in August with a panel covering 5 common inherited conditions. Expanded to cover 20 genes, leveraging proprietary SNP-based method. Positive initial feedback.
Signatera: Achieved record growth with 21,500 additional units in Q3. ASPs now at $1,200. Strong clinical adoption and new evidence generation, including Level 1A evidence in bladder cancer.
Women's Health: Solid sequential quarterly growth driven by interest in Fetal Focus.
Oncology: Strong growth with groundbreaking clinical data and adoption of Signatera.
Revenue: Generated $592 million in Q3, up 35% YoY. Raised 2025 revenue guidance to $2.18-$2.26 billion.
Gross Margin: Improved to 64.9% in Q3, up nearly 1.5 percentage points from Q2.
Free Cash Flow: Substantially raised guidance, expecting $100 million for the full year.
R&D Investments: Increased to support MolDx coverage for Signatera and FDA-enabling FIND study for early cancer detection.
Clinical Trials: Doubling down on evidence generation with 7 new MolDx submissions and interventional trials for MRD.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory hurdles: The company is investing heavily in clinical trials and data generation to support MolDx coverage for remaining Signatera indications and FDA-enabling FIND study for early cancer detection. These efforts are critical for reimbursement and market expansion but carry risks of delays or non-approval.
Operational costs: The company has incurred $60 million in one-time expenses this year and is increasing R&D spending to support new product launches and clinical trials. While these investments are strategic, they could strain financial resources if not managed effectively.
Market competition: The company faces competitive pressures in the ctDNA testing space, as other assays are also being developed. Differences in assay performance and trial designs could impact market share and adoption rates.
Economic uncertainties: The company is making significant investments in R&D and commercial operations, which could be impacted by broader economic conditions, potentially affecting cash flow and profitability.
Supply chain and technology risks: The company relies on advanced technologies like AI and proprietary methods for product development and operational efficiency. Any disruptions or failures in these technologies could adversely affect performance.
Strategic execution risks: The company is launching multiple new products and expanding its market presence. Missteps in execution, such as delays in product launches or failure to achieve expected adoption rates, could impact financial and operational performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company has raised its 2025 revenue guidance by $160 million at the midpoint, now expecting revenues in the range of $2.18 billion to $2.26 billion.
Gross Margin Guidance: Gross margin guidance has been increased to 62% to 64%, reflecting strong performance in the first three quarters and continued momentum in ASP and COGS.
Free Cash Flow Guidance: The company is substantially raising its guidance for free cash flow generation, now expecting to generate approximately $100 million in cash for the full year.
Operational Expenditure (OpEx) Guidance: OpEx guidance has been modestly increased due to one-time expenses totaling around $60 million and a small increase in R&D to support MolDx coverage for remaining Signatera indications.
MolDx Submissions: The company plans to submit 7 new MolDx submissions by the end of the year, which could generate $250 million to $300 million in gross profit based on current run rates.
Clinical Trials and FDA-Enabling Studies: Investments are being made to expand the market through definitive MRD trials and to support the FDA-enabling FIND study for early cancer detection, with patient enrollment continuing into 2026.
Product Launches: The company is expanding its Fetal Focus product to cover over 20 genes by the end of the year, following positive feedback from its initial launch in August.
2026 Preliminary Outlook: Volume growth for women's health and organ health is expected to remain stable, while Signatera units are projected to grow based on the last 4 quarters' rolling average. Modest ASP growth for Signatera is anticipated, potentially in the $50 range.
Advanced Adenoma Detection: The company is focusing on advanced adenoma detection with a sensitivity of approximately 22% to 24% and specificity of 91.5%, as part of its early cancer detection efforts.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is now the right time to launch the new Fetal Focus test, and how is the company thinking about reimbursement for the 20-gene panel?
A:The company launched the 5-gene panel earlier this summer, which has been well-received. R&D advancements have enabled the launch of the broader 20-gene panel, which was always part of the plan. The company is also excited about the EXPAND clinical trial, which is considered the gold standard for these types of trials.
Q:How is the company thinking about the path to NCC guidelines for MRD and broader commercial payer adoption?
A:The IMvigor011 data is Level 1A clinical data and has been submitted for FDA approval. If approved, it is expected to be included in NCCN guidelines. The company anticipates a guideline update mid or late next year. Commercial payers are showing traction due to biomarker bills and the quantity of evidence being generated.
Q:How important was the PROCEED-CRC study's performance in shaping the company's willingness to invest in early cancer detection, and what are the investment expectations for 2026?
A:The performance of the PROCEED-CRC study was crucial in shaping the decision to invest in early cancer detection. The company initiated the FIND study based on positive results from PROCEED. Investment in 2026 is expected to be around $50 million, and the company is optimistic about being a major player in the early cancer detection space.
Q:What is driving the growth in Signatera, and is there any concern about potential deceleration?
A:Growth is driven by new customers, extended usage by existing accounts, and new histologies. Despite strong growth in new patient starts, the company remains cautious about potential normalization over time. However, early Q4 trends indicate continued strong interest.
Q:What is the impact of biomarker bills on Signatera's adoption, and when will they have a broader impact?
A:Biomarker bills are contributing to ASP growth, with early progress seen in biomarker states. The company expects a continued drumbeat of reimbursement growth over 2026, with broader coverage being inevitable as clinical utility and cost savings become evident.
Q:Why does the company believe its assay is better suited to address issues like low signal abundance in ctDNA?
A:The company has focused on finding the best biomarkers, prioritizing advanced adenoma, and leveraging advanced technology for increased molecular recovery and differentiation of methylated regions. Access to a large repository of early-stage colon cancer cases has also been beneficial.
Q:When should the VEGA trial read out, and what factors contribute to its design?
A:The VEGA trial is expected to read out in 2027. All patients have been randomized, and the study design includes serial testing and crossover options. The company has confidence in the assay's performance based on data from the GALAXY study.
Q:What is the company's strategy for the Fetal Focus product, and how does it plan to capture market share?
A:The Fetal Focus product addresses clinical needs when the father is unavailable for testing. The company plans to roll it out broadly through its existing sales team and believes it has a competitive advantage due to its technology and clinical trials.
Q:What is the company's long-term strategy in early cancer detection, and when can updates on multi-cancer applications be expected?
A:The focus is currently on CRC, but the company is exploring multi-cancer applications in the background. Updates on multi-cancer applications will be provided as the CRC product progresses through clinical trials and market approval.
Q:What are the expectations for Signatera's 2026 volume growth and gross margins?
A:The company expects sequential unit volume growth to align with the rolling 4-quarter average of approximately 18,000. Gross margins are expected to improve meaningfully over the course of next year, with a long-term target of 70%.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the minimum viable performance for early cancer detection products, the exact timing of biomarker bill impacts, and the precise readout timeline for the VEGA trial. Additionally, responses on gross margin improvements and Signatera's ASP growth were somewhat vague, relying on general trends and expectations rather than concrete data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
COGS
CheckMate
ECD
England Journal
FDA FIND
Fetal Focus
Focus gene
IMvigor trial
INTERCEPT study
Journal Medicine
Latitude
MolDx
New England
Number
adenoma
adoption
blood
cancer detection
clearance
cohort
condition
depth
detection rate
grade
inheritance
lesion
marker
mother
mutation
panel
parent
percentage point
response
role
sensitivity specificity
slide volume
subtype
therapy
unit record
NTRA Transcript
Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-12
Natera, Inc. (NTRA) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call indicates strong growth in MRD tests, positive developments in women's health and oncology segments, and promising progress in international markets like Japan. Although there are concerns about gross margins and SG&A expenses, the company's cautious guidance allows room for upside. The Q&A session reveals optimism in new product launches and partnerships, with potential revenue growth from MolDX submissions. Despite some uncertainties, the overall sentiment is positive, suggesting a likely stock price increase in the short term.
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-12
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Neutral3-5
NTRA Slides
NTRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
